|
Session 157
Poster Abstracts
Changes in Bone Mineral Density
Tuesday, 1-4 pm
Room: Hall B |
965
 |
Short-term Bone Loss in HIV-infected Premenopausal Women
Michael Yin*1, S Cremers1, D Lu2, E Shane1, W Gao2, D McMahon1, and K Anastos2
1Columbia Univ Med Ctr, New York, NY, US and 2Montefiore Med Ctr, Bronx, NY, US |
966
|
Bone Mineral Density 96 Weeks after ART Initiation: A Randomized Trial Comparing Efavirenz-based Therapy with a Lopinavir/Ritonavir-containing Regimen with Simplification to LPV/r Monotherapy
Todd Brown*1, G McComsey2, M King3, R Qaqish3, B Bernstein3, and B da Silva3
1Johns Hopkins Univ, Baltimore, MD, US; 2Case Western Reserve Univ, Cleveland, OH, US; and 3Abbott Labs, Abbott Park, IL, US |
967
|
First-line PI-containing Regimens Enhance Decreased Bone Mineral Density Greater than NNRTI-containing Regimen in HIV-1-infected Patients: A Substudy of the HIPPOCAMPE–ANRS 121 Trial
C Duvivier1,2,3, S Kolta4, L Assoumou2,3, J Ghosn1,2,3, S Rozenberg5, R Murphy1,2, C Katlama1,2,3, Dominique Costagliola*2,3, and the ANRS 121 Study Group
1Hosp Pitie-Salpetriere, Paris, France; 2Univ Pierre and Marie Curie, Paris, France; 3INSERM UMR S720, Paris, France; 4Hosp Cochin, Univ Paris-Descartes, Paris, France; and 5Hosp Pitie-Salpetriere, Paris, France |
968
|
Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study
Christoph Fux*1, A Rauch1, M Simcock2,3, H Bucher2,3, B Hirschel4, M Opravil5, P Vernazza6, M Cavassini7, E Bernasconi8, H Furrer1, and Swiss HIV cohort Study (SHCS)
1Univ Hosp Berne, Switzerland; 2Basel Inst for Clin Epi, Basel, Switzerland; 3Univ Hosp Basel, Switzerland; 4Geneva Univ Hosp, Switzerland; 5Univ Hosp Zurich, Switzerland; 6Kantonsspital, St Gallen, Switzerland; 7Ctr Hosp Univ Vaudois Lausanne, Switzerland; and 8Hosp Civico, Lugano, Switzerland |
969
|
Risk Factors for Reduced Bone Mineral Density in HIV-infected Individuals in the Modern HAART Era
Silvia Guillemi*, F Ng, W Zhang, V Lima, C Rocha, M Harris, G Bondy, A Belzberg, and J Montaner
BC Ctr for Excellence in HIV/AIDS, Providence Hlth Care and Univ of British Columbia, Vancouver, Canada |
970
|
Reduced Bone Mineral Density in HCV- or HBV-co-infected Patients: 2-year Follow-up, ANRS CO3 Aquitaine Cohort, France
Charles Cazanave*1,2, M Dupon1,2, V Lavignolle-Aurillac3, N Barthe2, S Lawson-Ayayi1,2,3, N Mehsen2, D Lacoste1,2, J L Pellegrin1,2, D Neau1,2,3, F Dabis1,2,3, and for the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)
1COREVIH-Aquitaine, France; 2Bordeaux Univ Hosp, France; and 3INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, Bordeaux, France |
|
